Alaska Clinical Research Center

Alaska Clinical ResearchCenter
Alaska Clinical Research Center, LLC (ACRC) is an educational and research affiliate of Alaska Urological Institute, APC. It is a separate site and entity founded by a team of urologists dedicated to conducting clinical research trials in urology.

Our primary objective is to provide optimal patient care by giving patients access to a broad spectrum of treatment alternatives, and a greater understanding of new therapies.
For Medical Professionals

All Research Studies (on ClinicalTrials.gov)

Clinical Research Experience

Therapeutic Areas:

  • Urology
  • Urogynecology
  • Urologic Oncology
  • Nephrology
  • Sexual Dysfunction

Our research is specialized to any of our therapeutic specialties, and encompass clinical trials in all phases of study. (Phases II, III, and IV).

  • Erectile Dysfunction
  • Hypogonadism
  • Prostate Cancer
  • Prostatitis
  • Benign Prostatic Hypertrophy (BPH)
  • Pyelonephritis / Urinary Tract Infections
        - complicated & uncomplicated
  • Bladder Cancer
  • Urolithiasis
  • Urinary Incontinence
  • Interstitial Cystitis

Our center has worked with the following:

CRO’s:
PPD Development, Quintiles, Covance, Phoenix International, Kendle, The Phoenix, i3 Research, Inc., ILEX Oncology, Diagnostic Oncology

For Patients
Browse the active studies below to learn about eligibility for patient participation.
Study of Immunotherapy to Treat Advanced Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer
Condition: Prostatic Neoplasms
Interventions: Drug: placebo + docetaxel/prednisone; Drug: dasatinib + docetaxel/prednisone
Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: TAK-700; Drug: Docetaxel; Drug: Prednisone
The Safety and Effectiveness of AA4500 in Subjects With Peyronie's Disease Auxilium Pharmaceuticals, Inc.
Phase 3 study will start in Fall, 2010-05-10
Condition:  
Interventions:  
A Phase 3 Study of a Recombinant Vaccinia Virus Vaccine to Treat Metastatic Prostate Cancer (Prospect Study)
A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F ± GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer.
Condition: Metastatic Prostate Cancer
Interventions: Drug: Vaccine + GM-CSF; Drug: Vaccine + Placebo; Drug: Placebo/Placebo
A Phase 2 Study of MDV3100 (ASP9785) vs Bicalutamide to Treat Metastatic Prostate Cancer (Terrain Study)
A Randomized, Double-Blind, Phase II, Efficacy and Safety Study of MDV3100 (ASP8785) vs. Bicalutamide in Castrate Men with Metastatic Prostate Cancer.
Condition: Metastatic Prostate Cancer
Interventions: Drug: MDV3100; Drug: Bicalutamide
Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer
An Open-label Phase 1/2 Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer.
Condition: Prostate Cancer
Interventions: Drug: TAK-700; Drug: Docetaxel; Drug: Prednisone
Study of TAK-700 and Prednisone in Men with Metastatic Castration-Resistant Prostate Cancer Before Chemotherapy
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
The Elm.Pc - Studies for Metastatic Prostate Cancer
Condition: Metastatic Prostate Cancer
Interventions: Drug: TAK-700 (Orteronel); Drug: Prednisone; Drug: Placebo
Study of TAK-700 and Prednisone in Men with Metastatic Castration-Resistant Prostate Cancer after Chemotherapy
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed Following Docetaxel-based Therapy.
The Elm.Pc - Studies for Metastatic Prostate Cancer
Condition: Metastatic Prostate Cancer
Interventions: Drug: TAK-700; Drug: Prednisone; Drug: Placebo
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer
ACTIVE BUT CLOSED TO ENROLLMENT
Condition: Prostatic Neoplasms
Interventions: Drug: placebo + docetaxel/prednisone; Drug: dasatinib + docetaxel/prednisone
Study of Immunotherapy to Treat Advanced Prostate Cancer
Randomized, Double-Blind, Phase 3 Trial to Compare the Efficacy of Ipilimumab vs. Placebo in Asymptomatic or Minimally Symptomatic Patients with Metastatic Chemotherapy-Naïve Castration Resistant Prostate Cancer.
Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer (EMBARC-RF)
This is a phase 3 randomized, active-controlled, open-label, multicenter study that will be conducted in approximately 120 investigational sites worldwide. Subjects with either recurrent or refractory NMIBC (Ta high grade, T1 low or high grade, CIS) will be eligible for participation in this study.
Condition: Non-Muscle Invasive Recurrent or Refractory Bladder Cancer
Interventions: Drug: EN3348; Drug: Mitomycin
A Study to Assess Efficacy and Safety With VESIcare® to Improve Urinary Continence in Subjects After Robotic Assisted Radical Prostatectomy
A Randomized, Double-Blind, Parallel, Placebo Controlled, Phase 4, Multi-center Study to Assess Efficacy and Safety of VESIcare® (Solifenacin Succinate) to Improve Urinary Continence of Subjects after Robotic Assisted Radical Prostatectomy.
Condition: Urinary Incontinence after Robotic Radical Prostatectomy
Interventions: Drug: VESIcare; Drug: Placebo